A guide to the treatment of lower respiratory tract infections.

Abstract:

:Acute bronchitis is usually a viral infection which, unless there is a special disposition, does not require antibiotic therapy. For the initial oral chemotherapy of bacterial infections of the lower respiratory tract (chronic bronchitis, pneumonia) the effective and well tolerated cephalosporins, macrolides and amoxicillin plus beta-lactamase-inhibitor are recommended. In complicated cases with severe underlying disease, longer history or frequent exacerbations, quinolones should be given if Gram-negative infections are suspected or if initial therapy with other substances has failed. If Legionella, Mycoplasma or Chlamydia spp., so-called 'atypical' pathogens, are involved, macrolide antibiotics are the therapy of first choice. Special attention should be given to the increase in resistance against cotrimoxazole (trimethoprim-sulfamethoxazole) and tetracyclines. In hospitals where primary pneumonias are treated preferentially by intravenous medication, therapy should be switched to oral antibiotics as soon as feasible (follow-up therapy). For severely ill patients with secondary pneumonia and underlying disease, second generation cephalosporins with aminoglycosides, or monotherapy with third generation cephalosporins are recommended. In very severe, high-risk cases, third generation cephalosporins, combinations with high-dosage quinolones or ureidopenicillins plus beta-lactamase-inhibitors are suitable. Future development in the antibiotic treatment of respiratory infections will follow the current trend of lower dosages, with the clear objective of shortening treatment periods and achieving earlier discharge from hospital.

journal_name

Drugs

journal_title

Drugs

authors

Vogel F

doi

10.2165/00003495-199550010-00006

subject

Has Abstract

pub_date

1995-07-01 00:00:00

pages

62-72

issue

1

eissn

0012-6667

issn

1179-1950

journal_volume

50

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.

    abstract::The prevalence of use of long-term systemic glucocorticoid therapy in the general adult population is 1 %. This figure increases to up to 3 % in elderly women. Metabolic (i.e. diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e. hypertension, cardiovascular events) adverse events are c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0282-9

    authors: Fardet L,Fève B

    更新日期:2014-10-01 00:00:00

  • A new strategy for the treatment of inflammatory pain. Prevention or elimination of central sensitization.

    abstract::The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be unders...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400475-00003

    authors: Woolf CJ

    更新日期:1994-01-01 00:00:00

  • Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women.

    abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666170-00001

    authors: Mitwally MF,Casper RF

    更新日期:2006-01-01 00:00:00

  • Continuous-use ethinylestradiol/levonorgestrel 20microg/90microg: as an oral contraceptive.

    abstract::The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20microg/90microg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. Amenorrhoea and absence of breakthrough bleeding increase in incidence with extended administration....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767160-00010

    authors: Wagstaff AJ

    更新日期:2007-01-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Management of travellers' diarrhoea.

    abstract::The most common health problem encountered in international travellers to topical and subtropical areas is diarrhoea. Even though it is not a life-threatening condition, it may influence deeply the quality of a vacation or the success of a business trip. The majority of cases of travellers' diarrhoea are due to bacter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856010-00007

    authors: Caeiro JP,DuPont HL

    更新日期:1998-07-01 00:00:00

  • Treatment of gastroenteritis in children.

    abstract::Mortality and morbidity in gastroenteritis in children is the result of fluid loss, acid-base and electrolyte imbalance. Hence therapy should be aimed at preventing or correcting this imbalance. The use of intestinal antibiotics to treat the condition should not be a routine, but parenteral antibiotic therapy in the p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611040-00004

    authors: Tan G

    更新日期:1976-01-01 00:00:00

  • Digoxin use in congestive heart failure. Current status.

    abstract::The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855060-00002

    authors: Riaz K,Forker AD

    更新日期:1998-06-01 00:00:00

  • Biochemistry and pharmacology of the renin-angiotensin system.

    abstract::Knowledge of the structure, function and distribution of the components of the renin-angiotensin-aldosterone system (RAS) and the integrated physiological role of this hormonal system is rapidly increasing, although many questions remain unanswered. The primary structure and localisation of RAS such as renin, prorenin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199000391-00005

    authors: Johnston CI

    更新日期:1990-01-01 00:00:00

  • Effects of non-narcotic analgesics on the liver.

    abstract::Serious hepatotoxicity is uncommon with the proper therapeutic use of non-narcotic analgesics but experience with new non-steroidal anti-inflammatory drugs (NSAIDs) is limited. Drugs such as ibufenac, fenclofenac and benoxaprofen were withdrawn from the market because of hepatotoxicity, and liver damage has been repor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600324-00010

    authors: Prescott LF

    更新日期:1986-01-01 00:00:00

  • Treatment of nausea and vomiting in terminally ill cancer patients.

    abstract::Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/0003495-200868180-00004

    authors: Glare PA,Dunwoodie D,Clark K,Ward A,Yates P,Ryan S,Hardy JR

    更新日期:2008-01-01 00:00:00

  • Renal protection in hypertensive patients: selection of antihypertensive therapy.

    abstract::Hypertension is common in chronic renal disease and is a risk factor for the faster progression of renal damage, and reduction of blood pressure (BP) is an efficient way of preventing or slowing the progression of this damage. International guidelines recommend lowering BP to 140/90 mm Hg or less in patients with unco...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565002-00005

    authors: Wenzel RR

    更新日期:2005-01-01 00:00:00

  • Quinolone activity against anaerobes: microbiological aspects.

    abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00012

    authors: Appelbaum PC

    更新日期:1995-01-01 00:00:00

  • Cefadroxil in the treatment of susceptible infections in infants and children.

    abstract::The efficacy and safety of cefadroxil in the treatment of paediatric patients with a wide variety of infections were evaluated in a multicentre clinical trial. This study included 395 infants and children with Group A streptococcal pharyngitis, sinusitis, otitis media, bronchitis, pneumonia or bronchopneumonia, urinar...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600323-00005

    authors: Puhakka H,Virolainen E

    更新日期:1986-01-01 00:00:00

  • Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

    abstract::The lipid-modifying profile of bezafibrate is characterised by marked decreases in elevated triglyceride levels, increases in high density lipoprotein (HDL) cholesterol levels and decreases in total and low density lipoprotein (LDL) cholesterol levels. Bezafibrate also reduces elevated levels of lipoprotein(a) [Lp(a)]...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652050-00008

    authors: Goa KL,Barradell LB,Plosker GL

    更新日期:1996-11-01 00:00:00

  • Combination antiretroviral therapy. Back to the future.

    abstract::HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatme...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500491-00008

    authors: Lange J

    更新日期:1995-01-01 00:00:00

  • Suicide and antidepressants.

    abstract::Depression is associated with a risk of suicide 13 to 30 times greater than in the general population, and antidepressants are among the drugs most frequently implicated in fatal overdose, resulting in a dilemma for the clinician. Suicidal thoughts are a core symptom of depression, and there is evidence that the selec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199200432-00005

    authors: Montgomery SA

    更新日期:1992-01-01 00:00:00

  • Dulaglutide: A Review in Type 2 Diabetes.

    abstract::Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01260-9

    authors: Scott LJ

    更新日期:2020-02-01 00:00:00

  • Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance.

    abstract::The current challenge facing clinicians is to develop pharmacotherapies that move beyond the treatment of symptoms towards a new agenda in cardiovascular therapeutics that includes interventions to actually prevent the development of end-stage coronary heart disease. The development of new strategies to alter the natu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700545-00003

    authors: Gibbons GH

    更新日期:1997-01-01 00:00:00

  • Optimum management of the discharging ear.

    abstract::Discharge from the ear can be the result of many disease processes. The ear may discharge blood, pus, cerebrospinal fluid (CSF) or wax. Keratosis obturans, stenosis of the external meatus and benign tumours of the external meatus all lead to wax build-up, which may cause recurrent attacks of otitis externa. Malignant ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243020-00008

    authors: Ruddy J,Bickerton RC

    更新日期:1992-02-01 00:00:00

  • Atenolol with and without nifedipine in the treatment of angina pectoris. Preliminary report.

    abstract::Atenolol and nifedipine have been shown to be effective single agents in angina pectoris, but reports suggest that additional benefits may be conferred by combining the 2 drugs. Therefore, to establish that the combination regimen was at least as effective as either atenolol or nifedipine alone, a multicentre study wa...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800354-00012

    authors: Sandberg M,Foale RA

    更新日期:1988-01-01 00:00:00

  • An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.

    abstract::This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0377-y

    authors: Elshoff JP,Cawello W,Andreas JO,Mathy FX,Braun M

    更新日期:2015-04-01 00:00:00

  • Guillain-Barré syndrome: epidemiology, pathophysiology and management.

    abstract::Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently af...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464060-00003

    authors: Kuwabara S

    更新日期:2004-01-01 00:00:00

  • Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

    abstract::Enalapril provides significant haemodynamic, symptomatic and clinical improvement when added to maintenance therapy with digitalis and diuretics in patients with congestive heart failure [NYHA (New York Heart Association) classes II to IV]. These effects are not attenuated during long term therapy. More significantly,...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198937020-00004

    authors: Todd PA,Goa KL

    更新日期:1989-02-01 00:00:00

  • Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

    abstract::The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565140-00004

    authors: Epstein BJ,Gums JG

    更新日期:2005-01-01 00:00:00

  • Fluoroquinolones and surgical prophylaxis.

    abstract::The objective of surgical prophylaxis is to prevent wound infections associated with surgery. The rates of wound infections vary according to the procedure: less than 3 infections per 100 for clean procedures; up to 4 per 100 for clean-contaminated procedures; and up to 9 per 100 for contaminated procedures. Surgical ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300453-00018

    authors: Dellamonica P,Bernard E

    更新日期:1993-01-01 00:00:00

  • Treatment of chronic schizophrenia.

    abstract::The comprehensive treatment of schizophrenia requires the full resources of a clinical team that is able to offer treatment for the acute psychotic state in a hospital environment, and appropriate rehabilitation following resolution of the florid symptoms. Following a second or subsequent relapse, maintenance therapy ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197714040-00004

    authors: Johnson DA

    更新日期:1977-10-01 00:00:00

  • Vitamin A acid: a review of its pharmacological properties and therapeutic use in the topical treatment of acne vulgaris.

    abstract::Vitamin A acid (retinoic acid: tretinoin) is a vitamin A derivative used in the topical treatment of acne. It acts by 'unseating' comedones, improvement developing slowly over a period of 2 to 3 or more months, and is also said to prevent the formation of new lesions. About three-quarters of patients with acne vulgari...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714060-00001

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-12-01 00:00:00

  • Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.

    abstract::Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic pleuromutilin with a chemical structure that contains a tricyclic core of five-, six-, and eight-membered rings and a 2-(4-amino-2-hydroxycyclohexy...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01443-4

    authors: Zhanel GG,Deng C,Zelenitsky S,Lawrence CK,Adam HJ,Golden A,Berry L,Schweizer F,Zhanel MA,Irfan N,Bay D,Lagacé-Wiens P,Walkty A,Mandell L,Lynch JP 3rd,Karlowsky JA

    更新日期:2020-11-28 00:00:00

  • Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

    abstract::Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0051-1

    authors: Keating GM

    更新日期:2013-05-01 00:00:00